FIELD: biotechnologies.
SUBSTANCE: invention refers to ligands in the form of synthetic peptide amides of a kappa-opiate receptor, and namely to agonists of the kappa-opiate receptor, which show a low inhibition degree of P450 CYP and a low degree of penetration into brain. According to the invention, synthetic peptide amide is described by the following formula:
EFFECT: pharmaceutical compositions containing the above compounds are suitable for prophylaxis and curing of pain and inflammation, which are related to different diseases and states.
19 cl, 11 dwg, 53 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SYNTHETIC PEPTIDE AMIDES | 2007 |
|
RU2500685C2 |
| FORMULATIONS FOR ORAL ADMINISTRATION OF KAPPA-OPIOID RECEPTOR AGONISTS | 2019 |
|
RU2835627C2 |
| HYDANTOIN MODIFIED MELANOCORTIN RECEPTOR LIGANDS | 2008 |
|
RU2450017C2 |
| METASTIN DERIVATIVES AND USE THEREOF | 2007 |
|
RU2454425C2 |
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| METASTIN DERIVATIVES AND APPLICATION THEREOF | 2006 |
|
RU2430107C2 |
| GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES | 2009 |
|
RU2560254C2 |
| LINEAR OR CYCLIC OLIGOPEPTIDES SHOWING AFFINITY TO OPIATE RECEPTORS, PHARMACEUTICAL COMPOSITION | 1993 |
|
RU2131438C1 |
| AMIDE-BASED PRODRUGS OF GLUCAGON SUPERFAMILY PEPTIDES | 2009 |
|
RU2550696C2 |
| PEPTIDE COMPOSITIONS | 2014 |
|
RU2725150C2 |
Authors
Dates
2014-03-27—Published
2007-11-13—Filed